BlueSphere Bio

Hear from our CEO, Keir J. LoIacono, Esq., in the Outsourced Pharma article below:

Today we are excited to announce our collaboration with NMDP BioTherapies to advance our TCR T-cell therapy into human trials. NMDP BioTherapies will provide healthy donor materials for our upcoming Phase 1/2a trial (TCX-101) of our first-in-human product (BSB-1001). The Phase 1/2a trial will evaluate BSB-1001 in combination with allogeneic stem cell transplant in patients with high-risk leukemias, including relapsed or refractory acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS). Learn more here: https://lnkd.in/g4C5kxdy

#ICYMI, last week we celebrated multiple milestones! The FDA cleared our IND application for our first-in-human Phase 1/2a trial evaluating BSB-1001 in patients with high-risk leukemias. We also announced a strategic collaboration with the National Cancer Institute (NCI) to advance treatments for a rare respiratory disease.   Learn more about these exciting developments in Ron Leuty's recent Biotech roundup here: https://lnkd.in/euzC7ZsK

#ICYMI our Chief Executive Officer, Keir J. LoIacono, Esq., participated in a panel discussion at this year’s BIO International Convention (Biotechnology Innovation Organization). The panel, moderated by @Angus Liu, was titled, “What’s Nex-T: Innovator Roundtable on T Cell Therapies in Oncology.” Keir and other industry leaders, including Dan Passeri, CEO of Cue Biopharma, Lola Fahoyin-Aje, MD, MPH, Director of the Office of Clinical Evaluation at the FDA, and David Fontana, Ph.D., Chief Operating and Chief Business Officer of Umoja Therapeutics, discussed the future of T cell-directed cancer therapies. 

We are excited to announce a strategic collaboration between BlueSphere Bio and the National Cancer Institute (NCI) aimed at revolutionizing treatment options for recurrent respiratory papillomatosis (RRP), a rare and challenging orphan disease. Our partnership with the NCI underscores our commitment to innovation and dedication to transforming patients' lives facing unmet medical needs.    The expansion into the rare, non-oncology disease space further highlights the potential of our TCR discovery platform, TCXpress™.   Learn more about our collaboration here: https://lnkd.in/euDS22ST

We are proud to announce a major milestone for BlueSphere Bio. The FDA (FDA) has cleared the IND application for our first-in-human Phase 1/2a trial evaluating BSB-1001 in combination with allogeneic stem cell transplant in patients with high risk leukemias, including relapsed/refractory AML, ALL and MDS. To learn more about BSB-1001 and our newly announced portfolio of product candidates, click here: https://bit.ly/4c27E5f

Today, we announced that our Chief Executive Officer, Keir J. LoIacono, Esq., will be presenting a corporate update and be participating in a panel discussion titled “What’s Nex-T: Innovator Roundtable on T Cell Therapies in Oncology” at the 2024 BIO International Convention, held from June 3 to 6, 2024, in San Diego, California. Learn more here: https://bit.ly/3R61jha

Join our Chief Scientific Officer, Zhimei Du, as she takes the stage this afternoon at 4:00 pm ET to present her talk titled, “Developing Novel TCR-Based Therapies for Hematologic Malignancies and Solid Tumors.” Secure your spot and register now for the PEGS Boston Summit here: https://www.pegsummit.com/

Join our Chief Scientific Officer, Zhimei Du, as she takes the stage this afternoon at the Essential Protein & Antibody Engineering Summit in Boston, MA. Don’t miss her opening remarks as day two of the summit kicks off at 2:55pm ET. Secure your spot and register now for the PEGS Boston Summit here: https://www.pegsummit.com/

Check out our CEO, Keir J. LoIacono, Esq., and his conversation with Factor below!